Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

5.1K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
5.1K
Chronic Obstructive Pulmonary Disease-I: Introduction01:20

Chronic Obstructive Pulmonary Disease-I: Introduction

4.1K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
4.1K
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

2.2K
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
2.2K
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

870
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
870
Chronic Obstructive Pulmonary Disease01:24

Chronic Obstructive Pulmonary Disease

3.2K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
3.2K
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

4.2K
The pathophysiology of pneumonia involves the following steps:
4.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Predictive role of natural killer cells in bronchoalveolar lavage fluid of patients with sarcoidosis.

Pulmonology·2024
Same author

[Linguistic Validation of the "German Lung Fibrosis Health Related Quality of Life Questionnaire"].

Pneumologie (Stuttgart, Germany)·2021
Same author

[German Guideline for Idiopathic Pulmonary Fibrosis].

Pneumologie (Stuttgart, Germany)·2020
Same author

[German Guideline for Idiopathic Pulmonary Fibrosis].

Pneumologie (Stuttgart, Germany)·2020
Same author

[E-Cigarettes - Operating Principle, Ingredients, and Associated Acute Lung Injury].

Pneumologie (Stuttgart, Germany)·2020
Same author

[Treatment of systemic sclerosis-associated interstitial lung disease].

Zeitschrift fur Rheumatologie·2019

Related Experiment Video

Updated: Apr 1, 2026

Refined Murine Model of Idiopathic Pulmonary Fibrosis
07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

1.3K

[Idiopathic Pulmonary Fibrosis].

A Prasse1

  • 1Medizinische Hochschule Hannover, Abteilung für Pneumologie.

Pneumologie (Stuttgart, Germany)
|October 8, 2015
PubMed
Summary

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease primarily affecting the elderly. Recent advancements include two approved treatments, pirfenidone and nintedanib, offering new hope for patients.

Area of Science:

  • Pulmonology
  • Interstitial Lung Diseases

Background:

  • Idiopathic pulmonary fibrosis (IPF) is the most common interstitial pneumonia, predominantly affecting older adults.
  • Risk factors include cigarette smoking, environmental exposures, and genetic predisposition.
  • IPF is characterized by the idiopathic form of Usual Interstitial Pneumonitis (UIP).

Purpose of the Study:

  • To provide an overview of Idiopathic Pulmonary Fibrosis (IPF).
  • To discuss the diagnostic challenges and current treatment landscape of IPF.

Main Methods:

  • Review of existing literature on IPF.
  • Analysis of diagnostic criteria for IPF.
  • Summary of approved therapeutic agents for IPF.

Main Results:

More Related Videos

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

2.2K
Adoptive Transfer of IL-33-Stimulated Macrophages into Bleomycin-Induced Mouse Models to Study Their Effect on Idiopathic Pulmonary Fibrosis In Vivo
06:29

Adoptive Transfer of IL-33-Stimulated Macrophages into Bleomycin-Induced Mouse Models to Study Their Effect on Idiopathic Pulmonary Fibrosis In Vivo

Published on: May 5, 2023

3.3K

Related Experiment Videos

Last Updated: Apr 1, 2026

Refined Murine Model of Idiopathic Pulmonary Fibrosis
07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

1.3K
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

2.2K
Adoptive Transfer of IL-33-Stimulated Macrophages into Bleomycin-Induced Mouse Models to Study Their Effect on Idiopathic Pulmonary Fibrosis In Vivo
06:29

Adoptive Transfer of IL-33-Stimulated Macrophages into Bleomycin-Induced Mouse Models to Study Their Effect on Idiopathic Pulmonary Fibrosis In Vivo

Published on: May 5, 2023

3.3K
  • Diagnosis of IPF requires exclusion of other UIP-pattern diseases.
  • Lung transplantation remains the only definitive cure for IPF.
  • Pirfenidone and nintedanib represent significant therapeutic advancements.

Conclusions:

  • IPF is a complex disease with multifactorial etiology.
  • Current management focuses on slowing disease progression and improving quality of life.
  • The approval of new drugs marks a breakthrough in IPF treatment.